

# 1 Title

2 A deep intronic variant in *MME* causes autosomal recessive Charcot-Marie-Tooth neuropathy  
3 through aberrant splicing.

# 4 Authors

5 Bianca R Grosz<sup>1,2</sup>, Jevin M Parmar<sup>3,4</sup>, Melina Ellis<sup>1,2</sup>, Samantha Bryen<sup>5,6</sup>, Cas Simons<sup>5,6</sup>,  
6 Andre L.M. Reis<sup>5,7,8</sup>, Igor Stevanovski<sup>5,7</sup>, Ira W. Deveson<sup>5,7,8</sup>, Garth Nicholson<sup>2,11</sup>, Nigel  
7 Laing<sup>3</sup>, Mathew Wallis<sup>9,10</sup>, Gianina Ravenscroft<sup>3</sup>, Kishore R. Kumar<sup>2,11,12,13</sup>, Steve Vucic<sup>2,14</sup>,  
8 Marina L Kennerson<sup>1,2,11</sup>

9 ORCID:

10 Bianca R Grosz: 0000-0002-6926-0551

11 Jevin Parmar: 0000-0003-1864-8094

12 Melina Ellis: 0000-0002-8542-048X

13 Samantha Bryen: 0000-0002-4140-8622

14 Cas Simons: 0000-0003-3147-8042

15 Andre L.M Reis: 0000-0002-7300-1157

16 Igor Stevanovski: 0000-0002-7713-1979

17 Ira W Deveson: 0000-0003-3861-0472

18 Mathew Wallis: 0000-0002-5441-1732

19 Garth A Nicholson: 0000-0001-9694-066X

20 Nigel Laing: 0000-0001-5111-3732

21 Gianina Ravenscroft: 0000-0003-3634-211X

22 Kishore R Kumar: 0000-0003-3482-6962

23 Marina L Kennerson: 0000-0003-3332-5074

24

25 Affiliations:

- 26 1. Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, NSW 2139,
- 27 Australia
- 28 2. The University of Sydney, Camperdown, NSW, 2050, Australia
- 29 3. Rare Disease Genetics and Functional Genomics Research Group, Harry Perkins
- 30 Institute of Medical Research, QEII Medical Centre, Nedlands, Western Australia,
- 31 6009, Australia
- 32 4. Centre for Medical Research, Faculty of Health and Medical Sciences, The University
- 33 of Western Australia, Perth, WA 6009, Australia
- 34 5. Centre for Population Genomics, Garvan Institute of Medical Research, and UNSW
- 35 Sydney, Sydney, NSW, Australia
- 36 6. Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne,
- 37 VIC, Australia
- 38 7. Genomics and Inherited Disease Program, Garvan Institute of Medical Research,
- 39 Sydney, NSW, Australia.
- 40 8. Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
- 41 9. Tasmanian Clinical Genetics Service, Tasmanian Health Service, Hobart, TAS,
- 42 Australia.
- 43 10. School of Medicine and Menzies Institute for Medical Research, University of
- 44 Tasmania, Hobart, TAS, Australia.
- 45 11. Molecular Medicine Laboratory and Neurology Department, Concord Repatriation
- 46 General Hospital, Hospital Rd, Concord, NSW, 2139, Australia
- 47 12. Translational Neurogenomics Group, Genomic and Inherited Disease Program, The
- 48 Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010,
- 49 Australia
- 50 13. St Vincent's Healthcare Campus, Faculty of Medicine, UNSW Sydney, Level 5, De
- 51 Lacy Building, St Vincent's Hospital, Darlinghurst, NSW, 2010, Australia.
- 52 14. Brain and Nerve Research Centre, The University of Sydney, Sydney, NSW 2139,
- 53 Australia

54

55

56

## 57 Abstract

58 **Background:** Loss-of-function variants in *MME* (membrane metalloendopeptidase) are a  
59 known cause of recessive Charcot-Marie-Tooth Neuropathy (CMT). A deep intronic variant,  
60 *MME* c.1188+428A>G (NM\_000902.5), was identified through whole genome sequencing  
61 (WGS) of two Australian families with recessive inheritance of axonal CMT using the seqr  
62 platform. *MME* c.1188+428A>G was detected in a homozygous state in Family 1, and in a  
63 compound heterozygous state with a known pathogenic *MME* variant (c.467del;  
64 p.Pro156Leufs\*14) in Family 2.

65 **Aims:** We aimed to determine the pathogenicity of the *MME* c.1188+428A>G variant  
66 through segregation and splicing analysis.

67 **Methods:** The splicing impact of the deep intronic *MME* variant c.1188+428A>G was  
68 assessed using an *in vitro* exon-trapping assay.

69 **Results:** The exon-trapping assay demonstrated that the *MME* c.1188+428A>G variant  
70 created a novel splice donor site resulting in the inclusion of an 83 bp pseudoexon between  
71 *MME* exons 12 and 13. The incorporation of the pseudoexon into *MME* transcript is predicted  
72 to lead to a coding frameshift and premature termination codon (PTC) in *MME* exon 14  
73 (p.Ala397ProfsTer47). This PTC is likely to result in nonsense mediated decay (NMD) of  
74 *MME* transcript leading to a pathogenic loss-of-function.

75 **Interpretation:** To our knowledge, this is the first report of a pathogenic deep intronic *MME*  
76 variant causing CMT. This is of significance as deep intronic variants are missed using whole  
77 exome sequencing screening methods. Individuals with CMT should be reassessed for deep  
78 intronic variants, with splicing impacts being considered in relation to the potential  
79 pathogenicity of variants.

80 **Key Words** (up to 5): Charcot-Marie-Tooth disease, splicing, *MME*, recessive, deep intronic

## 81 Introduction

82 Charcot-Marie-Tooth neuropathy (CMT) is the most common inherited peripheral  
83 neuropathy, affecting 1/2500 individuals<sup>1</sup>. CMT is characterized by progressive length-  
84 dependent loss of peripheral motor and sensory nerves, resulting in distal muscle weakness  
85 and sensory symptoms<sup>2</sup>. Patients are broadly divided into subtypes based on whether nerve  
86 conduction studies (NCS) indicating demyelinating (CMT1) or axonal (CMT2) forms of the  
87 disease. Recessive loss-of-function variants in the membrane metalloendopeptidase (*MME*)  
88 gene have been previously reported to cause axonal Charcot-Marie-Tooth neuropathy type 2T  
89 (CMT2T; OMIM: #617017)<sup>3–11</sup>. *MME* encodes for neprilysin, a widely expressed membrane-  
90 bound metallopeptidase that has a key role in neuropeptide processing<sup>12</sup>. A significant portion  
91 of patients with axonal CMT remain genetically undiagnosed<sup>13–17</sup>, indicating that further  
92 disease-causing genes and pathogenic variants in known genes are yet to be identified.

93 Splicing variants are increasingly being recognized as a cause of Mendelian disease<sup>18,19</sup>. The  
94 precise removal of introns (non-coding regions) and inclusion of exons (coding regions) in  
95 the final mature mRNA relies on the spliceosome and auxiliary splicing factors recognizing  
96 specific sequence motifs, such as the 5' donor splice site and 3' acceptor splice site. Splice-  
97 altering variants can weaken or abolish recognition of the correct splice sites, or alternatively  
98 strengthen or create cryptic splice sites that mimic consensus splicing sequences<sup>20</sup>. These  
99 variants typically lead to one or more mis-splicing events that result in the skipping of partial  
100 or complete exons, and/or the retention of partial or complete introns<sup>21–42</sup>. Pathogenic  
101 splicing variants have been found in several CMT genes including *MPZ*<sup>21,30,39,40</sup>,  
102 *MFN2*<sup>22,30,31</sup>, *LRSAM1*<sup>23</sup>, *IGHMBP2*<sup>24</sup>, *INF2*<sup>25</sup>, *MCM3AP*<sup>26</sup>, *SH3TC2*<sup>30,32,38</sup>, *GDAP1*<sup>27,42</sup>,  
103 *SBF1*<sup>28</sup>, *NDRG1*<sup>37</sup>, and *FGD4*<sup>29</sup>. Variants affecting canonical splice donor and acceptor sites  
104 have also been described in *MME*<sup>4,41</sup>.

Exon-trapping, also known as a mini-gene assay, is an *in vitro* technique used to identify exons in a genomic region of interest<sup>43</sup>. This is of particular use when relevant patient tissue is unavailable or when relevant transcripts may be unstable or degraded by nonsense mediated decay (NMD)<sup>44</sup>. The genomic region of interest is cloned into an exon-trapping vector between two known exons. This exon-trapping vector is transfected into a cell line where it is transcribed and undergoes a series of post-transcriptional processes that include pre-mRNA splicing to create mature mRNA. This mRNA consists of the ‘trapped’ exons of the genomic region of interest flanked by the known exons, which can then be Sanger sequenced to characterize the ‘trapped’ exons. Comparison of ‘trapped’ exons between wild type and variant genomic sequences can also indicate if a candidate variant affects splicing<sup>45–51</sup>. The well-validated exon-trapping vector pSpliceExpress<sup>52</sup> consists of known exons of the rat insulin gene, *Ins2*, and has been used previously to determine the splicing impacts of multiple pathogenic variants in Mendelian disease<sup>45–51</sup>.

Here we report a deep intronic variant in *MME* [chr3:155142758A>G (hg38); *MME* c.1188+428A>G], found in a recessive state in two Australian families. Exon-trapping revealed that this variant creates a novel splice donor site in *MME* intron 12 (NM\_000902.5) which, along with a preceding existing cryptic splice acceptor site, results in the incorporation of an 83 bp pseudoexon in the *MME* transcript [chr3:155,142,675-155,142,757 (hg38); r.1188\_1189ins[1188+345\_1188+427]]. The coding frameshift caused by this pseudoexon leads to a PTC in exon 14 and likely NMD of the *MME* transcript (p.Ala397ProfsTer47), resulting in a loss of *MME* function.

## Materials and Methods:

### Subjects

Members of Family 1 were recruited and informed consent was obtained for this study using protocols approved by the Sydney Local Health District Human Ethics Research Committee (2019/ETH07839). Recruitment and informed consent for the proband of Family 2 was approved by the Human Research Ethics Committee of the Royal Melbourne Hospital (HREC/16/MH/251).

### Variant Detection

Genomic DNA for Family 1 was extracted from peripheral blood using the PureGene Kit (Qiagen) following the manufacturer's instructions. WGS for two individuals in Family 1 (V:1 and V:3) was outsourced to the Garvan Sequencing Platform. Paired-end sequencing reads of 150 base pairs were generated using the Illumina NovaSeq 6000 sequencing machine, with 30-fold average read depth.

In Family 2, genomic DNA for the proband was extracted at the Department of Diagnostic Genomics (PathWest, Perth, Australia) using the QIAseq<sup>SP</sup> machine and QIAseq<sup>®</sup> DSP DNA Midi Kit. The proband underwent WGS at the Australian Genomics Research Facility (AGRF), Melbourne, following GATK4 best-practices. Paired-end sequencing reads of 150 base pairs were generated using the Illumina NovaSeq 6000 sequencing machine, with 30-fold average read depth. Parental DNA was not available for sequencing.

WGS data processing was performed at the Centre for Population Genomics (CPG) following the DRAGEN GATK best practices pipeline. Reads were aligned to the hg38 reference genome using Dragmap (v1.3.0). Cohort-wide joint calling of single nucleotide variants (SNVs) and small insertion/deletion (indel) variants was performed using GATK

HaploTypeCaller (v4.2.6.1) with “--dragen-mode” enabled. Sample sex and relatedness quality checks were performed using Somalier (v0.2.15)<sup>53</sup>. Variants were annotated using VEP 105, and loaded into the web-based variant filtration platform, seqr<sup>54</sup>. A WGS search was conducted using the seqr<sup>45</sup> platform for low minor allele frequency (<0.01) variants in CMT-related genes, for both Family 1 and 2 [gene list- Hereditary Neuropathy\_CMT\_IsolatedAndComplex (Version 2.14)<sup>55</sup>]. Additionally, variants were analyzed by the CPG Automated Interpretation Pipeline (AIP, <https://github.com/populationgenomics/automated-interpretation-pipeline>). *In silico* splicing analysis was conducted using SpliceAI<sup>56</sup>.

## Segregation Analysis

The *MME* c.1188+428A>G variant in Family 1 and Family 2 was amplified using primers that spanned *MME* intron 12 (5'-CTCAGCCGAACCTACAAGGA-3'; 5'-GCAAATGCTGCTTCCACAT-3') to produce a 1264 bp amplicon [chr3:155,142,289-155,143,552 (hg38)]. An internal sequencing primer was used (5'-CTGTGTAAAAGTAATTTTCGGGG-3') and the amplicon was Sanger sequenced. The *MME* c.467del variant in Family 2 was amplified (5'-GCAGAGCCGTATGCATCACT-3'; 5'-TTCAGCTGTCCAAGAAGCACC-3'). A 717bp amplicon was produced [chr3:155,116,171-155,116,887 (hg38)], which was subsequently Sanger sequenced.

## Sanger Sequencing

For Family 1, PCR amplicons were sent to Garvan Molecular Genetics, Garvan Institute (Sydney, Australia) for Sanger sequencing using BigDye Terminator cycle sequencing protocols. For Family 2, proband PCR amplicons were Sanger sequenced at AGRF, Perth using BigDye Terminator sequencing protocols. Sequences were visualized and analyzed using Snapgene Software version 7.1 ([www.snapgene.com](http://www.snapgene.com)).

## Oxford Nanopore Technologies (ONT) Long Read Sequencing

High molecular weight (HMW) DNA samples of the Proband in Family 2 were transferred to the Garvan Sequencing Platform for targeted long-read sequencing analysis on ONT instruments. Prior to ONT library preparations, DNA was sheared to ~20-25 kb fragment size using a MegaRuptor 3 instrument and visualized post-shearing on an Agilent FemtoPulse.

Sequencing libraries were prepared from ~3-5 µg of HMW DNA, using native library prep kit SQK-LSK114, according to manufacturer's instructions. Each library was loaded onto a R10.4.1 flow cell and sequenced on a PromethION device with live target selection/rejection executed by the ReadFish software package<sup>57</sup>. Detailed descriptions of software and hardware configurations used for ReadFish are provided in a previous publication<sup>58</sup>. Samples were run for a maximum duration of 72 h, with nuclease flushes and library reloading performed at approximately 24- and 48-h timepoints for targeted sequencing runs, to maximize sequencing yield. Raw ONT sequencing data was converted to BLOW5 format<sup>59</sup> using slow5tools (v.0.3.0)<sup>60</sup> then base-called using Guppy (v6). Resulting FASTQ files were aligned to the hg38 reference genome using minimap2 (v2.14-r883)<sup>61</sup>. Variants were called using clair3<sup>62</sup>, phased using Whatshap<sup>63</sup> and visualized using the Integrative Genomics Viewer (IGV, v2.17.3)<sup>64</sup>.

## Cell Culture

The human HeLa cervical epithelial cell line (ATCC) was maintained in Dulbecco's Modified Eagle's Medium (DMEM)(Gibco) containing 10% (v/v) fetal bovine serum (FBS) (Gibco), +100 U/mL penicillin (Gibco), and 100 µg/mL streptomycin (Gibco) at 37°C in humidified air and 5% CO<sub>2</sub>.



## Cloning Procedures

The region surrounding *MME* c.1188+428A>G [chr3:155,141,790-155,143,755 (hg38)] was amplified from the genomic DNA of a heterozygous carrier of the c.1188+428A>G variant, using *attB* adapter primers (5'-AAAAAGCAGGCTTCGCTCTTAAATGGTTGGCTT-3'; 5'-AGAAAGCTGGGTAAGTACTCTTGGGGAAGGC-3'). The *MME* amplicon was then cloned into the exon-trapping pSpliceExpress vector between flanking *Ins2* exons using a two-step Gateway cloning BP reaction (ThermoFisher). pSpliceExpress was a gift from Stefan Stamm (Addgene plasmid #32485)<sup>52</sup>. The pSpliceExpress-*MME* clones were then Sanger sequenced to verify the correct insertion of *MME* and to determine the c.1188+428A>G genotype of each clone (as the genomic DNA template was heterozygous for the variant).

## *In vitro* exon-trapping

HeLa cells were grown to approximately 70% confluence in a 6-well plate. HeLa cells were separately transfected with either 2 µg of pSpliceExpress-*MME*<sub>WT</sub> or 2 µg of pSpliceExpress-*MME*<sub>c.1188+428A>G</sub> using Lipofectamine 3000 (ThermoFisher). RNA extraction was performed 48 h following transfection using the RNEasy Mini Kit (Qiagen), and reverse-transcribed template was prepared using the iScript cDNA Synthesis Kit (Bio-Rad). PCR amplification of cDNA was conducted using primers designed to anneal to the flanking *Ins2* exons (5'-CAGCACCTTTGTGGTTCTCA-3'; 5'-CAGTGCCAAGGTCTGAAGGT-3'). The RT-PCR amplicons were size fractionated using a 1.5% w/v agarose gel. The largest amplicon for each vector was gel-purified using Isolate II PCR and Gel Kit (Bioline) for Sanger Sequencing.

## *In silico* splicing analysis of reported *MME* variants

All reported *MME* variants in gnomAD v.4.0.0 were detected by searching the gnomAD browser for the genomic region corresponding with the *MME* gene; '3-155024124-155183704'(hg38). The *MME* variants reported in gnomAD were then exported using the

224 'Export Variants to CSV' function. The consequences of the variants were described by  
225 gnomAD using the Variant Effect Predictor (VEP) annotation based on the most deleterious  
226 predicted functional effect of each variant<sup>65</sup>. These variants were then filtered for a minor  
227 allele frequency (MAF) <0.01 and a maximum SpliceAI  $\Delta$ score >0.8 (high precision splicing  
228 change prediction<sup>66</sup>) as annotated by gnomAD.

229

230

231

## Results:

### Clinical Phenotypes

Family 1 consists of four affected siblings from a consanguineous family of European (non-Finnish) background (Figure 1a). The phenotype was consistent with a generalized sensorimotor axonal neuropathy and sensory ataxia without cerebellar signs (Table 1), and was confirmed with NCS for individuals V:1 and V:6 (Table 2). Affected individuals had previously undergone diagnostic and research whole exome sequencing with negative results.

Family 2 consists of one affected female born to a healthy, non-consanguineous couple (Figure 1b). Neurological examination revealed mild distal upper limb weakness and moderate distal lower limb weakness (Table 1). NCS showed evidence of an axonal sensorimotor neuropathy (Table 2). Bilateral MRI of the thighs and calves showed muscle atrophy (Supplementary Figure 1).

## Genetic Analysis

WGS screening using the seqr platform in Family 1 revealed a single homozygous variant in two affected individuals (V:1 and V:3), *MME* c.1188+428A>G (NM\_000902.5). This variant was reported in dbSNP build 155<sup>67</sup> (rs61758195), with a low MAF in gnomAD v4.0.0<sup>68</sup> (10/152120), All of Us (35/490,748)<sup>69</sup>, and TOPMED<sup>70</sup> (15/264290). No homozygous individuals were reported in gnomAD, All of Us, or TOPMED. SpliceAI predicted that *MME* c.1188+428A>G could create a strong novel splice donor site (Score 0.97; where a SpliceAI score above 0.8 is considered a ‘high precision’ predicted splice variant<sup>56</sup>). This in turn strengthened the SpliceAI prediction for a cryptic splice acceptor site 83 bp upstream of the novel splice donor site (Score 0.99).

Segregation analysis in Family 1 confirmed the biallelic inheritance of the *MME* c.1188+428A>G variant segregated with the CMT phenotype (Figure 1a). Sanger sequencing of DNA from available individuals showed that all affected individuals were homozygous for the *MME* c.1188+428A>G variant and unaffected individuals were carriers (Supplementary Figure 2).

WGS screening using the seqr platform and AIP was conducted in the proband of Family 2 (II:1). The *MME* c.1188+428A>G variant was detected in a compound heterozygous state with a second *MME* variant (*MME* c.467del; p.Pro156Leufs\*14), which has previously been reported as pathogenic<sup>41</sup> (Figure 1b). Sanger sequencing validated the presence of each *MME* variant in the index individual (Supplementary Figure 3). As parental DNA was unavailable, ONT long-read sequencing was conducted to phase the heterozygous *MME* variants in the proband (Figure 1c-d). ONT long-read sequencing confirmed that *MME* c.1188+428A>G (boxed red in Figure 1c) and c.467del (boxed red in Figure 1d) were present on alternative haplotypes (hap-1: red, hap-2: blue) and therefore were in *trans* in the proband.

## *In vitro* exon-trapping of *MME*-pSpliceExpress vectors

Two separate exon-trapping pSpliceExpress vectors were generated to assess the *in vitro* splicing impact of the *MME* c.1188+428A>G variant: pSpliceExpress-*MME*<sub>WT</sub> (wild-type) and pSpliceExpress-*MME*<sub>c.1188+428A>G</sub> (variant). A schematic of the constructs and relevant SpliceAI scores are shown in Figure 2a. RT-PCR products produced following transfection of these vectors were analyzed using gel electrophoresis (Figure 2b), which revealed a visible size difference between the wild-type (381 bp) and *MME* c.1188+428A>G amplicons (464 bp). The gel-purified amplicons were Sanger sequenced and the sequencing was aligned to the WT *MME* mRNA sequence. The sequenced products showed that the pSpliceExpress-*MME*<sub>WT</sub> produced a transcript that was correctly spliced between *MME* exon 12 and 13 (Figure 2c). In contrast, exon-trapping of the pSpliceExpress-*MME*<sub>c.1188+428A>G</sub> vector showed that an 83 bp pseudoexon had been spliced between *MME* exon 12 and 13 (Figure 2d). A BLAT search<sup>71</sup> using the sequence of the trapped pseudoexon revealed alignment to the intronic region directly upstream of the *MME* c.1188+428A>G variant [chr3:155,142,675-155,142,757 (hg38)]. This suggests that the *MME* c.1188+428A>G variant creates a novel splice donor site leading to the aberrant inclusion of 83 bp of intronic *MME* sequence in the final spliced transcript, as predicted by SpliceAI. Prediction of the novel *MME* coding sequence caused by the introduction of the pseudoexon showed that a PTC was generated in exon 14 (p.Ala397ProfsTer47) at genomic position chr3:155,144,368 (hg38) (Supplementary Figure 4). This PTC likely leads to NMD of the *MME* transcript.

## *In silico* splicing analysis of *MME* variants

All reported *MME* variants in gnomAD v.4.0.0 were assessed using the integrated SpliceAI scores to determine if splicing variants in *MME* were a likely underrecognized cause of disease. There were 37,264 total variants reported in *MME* in gnomAD, of which 35,673 variants had a MAF <0.01. Of these, 88 variants had a maximum SpliceAI  $\Delta$ score above 0.8

(Supplementary Table 1). There were no homozygotes reported for any of the 88 *MME* putative splicing variants. The majority of these predicted splicing variants were predicted to directly change either the canonical splice donor sites (26/88) or canonical splice acceptor sites (30/88) of *MME*, including an inframe deletion (c.1317\_1317+2del) and a frameshift variant (c.957+1del). An additional nine variants were predicted to affect a splicing region, including one which is also annotated as a synonymous variant (c.1188G>A; p.Lys396Lys). Nine missense variants (p.Asp209Gly, p.Ile217Ser, p.Glu282Val, p.Arg365Ile, p.Ser436Gly, p.Asp533Gly, p.Ile553Val, p.Val554Phe, p.Gln692Arg) and a synonymous variant (p.Gly417Gly) were also predicted to alter splicing. Twelve variants were annotated as ‘intron variants’, of which two could be considered ‘deep intronic’ variants (c.1188+428A>G, described in this manuscript, and c.197-9871A>G). Interestingly, further analysis using SpliceAI demonstrated that *MME* c.197-9871A>G was predicted to create a splice donor site (Score 0.81) and strengthen an upstream cryptic splice acceptor site (Score 0.81) in a similar manner to c.1188+428A>G, thereby possibly creating an in-frame 96 bp pseudoexon.

## Discussion

Here we report a deep intronic variant, *MME* c.1188+428A>G causing recessive CMT2T in two unrelated Australian families. This variant results in a pseudoexon that likely leads to NMD of the *MME* transcript, resulting in a loss-of-function. This is in keeping with previously reported *MME* variants which have broadly been characterised as ‘loss-of-function’ variants. To our knowledge, this is the first report of a pathogenic deep intronic variant in *MME*. Given that a significant portion of patients with axonal CMT remain genetically undiagnosed<sup>13-17</sup>, it’s possible that deep intronic variants in *MME* explain a portion of this diagnostic gap.

Individuals from Family 1 previously underwent both diagnostic WES and research WES, and the proband in Family 2 previously underwent targeted gene panel testing (PathWest neuro v3). These testing methods did not capture deep intronic regions and returned negative results. However, deep intronic regions have previously been shown to have a higher prevalence of variants than coding regions and canonical splice sites<sup>72</sup>. Our findings suggest that intronic SNPs should be analyzed to determine if they impact splicing before they are dismissed as benign. Detection and functional validation of deep intronic variants has previously been shown to increase diagnostic rates in other Mendelian diseases including X-linked Alport syndrome<sup>73</sup>, inherited retinal disorders<sup>74,75</sup>, and dystrophinopathy<sup>76,77</sup>. Pathogenic deep intronic variants, such as described here, are likely to be underreported amongst CMT-causing genes due to a lack of detection by WES and targeted gene panels, and a lack of functional investigation upon detection.

The *MME* c.1188+428A>G variant was reported in multiple different genetic ancestry groups in gnomAD v.4.0.0<sup>68</sup>, including in the European (Non-Finnish) (8/68008), African/African

American (1/41432), and ‘remaining’ (1/2092) ancestry groups. This was also reflected in the ‘All of Us’ Research Program<sup>69</sup>, which reported the *MME* c.1188+428A>G variant in the African (2/107,888) and European populations (33/256,804). Whilst it is possible that *MME* c.1188+428A>G represents a recurrent *de novo* variant, it is also likely that this variant has persisted at low levels in the global population. As this variant is missed by WES and may not be prioritised by variant-filtering approaches focusing on coding variants, this variant may therefore represent an underappreciated cause of recessive CMT. This is further supported by its detection in two Australian CMT families who are not known to be related.

Whilst the predicted splicing variants reported in *MME* are individually rare, we have described eighty-eight variants in gnomAD that are predicted by SpliceAI to alter splicing. Nine of these variants were annotated as missense variants, and one was a synonymous change. This is of note as these ‘missense’ variants are often assumed to result in a single amino acid change, and synonymous variants are often considered functionally neutral, with their effect on splicing typically not assessed<sup>78</sup>. Our results suggest that the discovery of any of these eighty-eight variants in a homozygous or compound heterozygous state in an individual with CMT should prompt further functional investigation of their effect on splicing of the *MME* transcript.

Prior to functional validation, *MME* c.1188+428A>G was considered a variant of uncertain significance (VUS) according to American College of Medical Genetics and Genomics (ACMG) criteria<sup>79</sup> (BP4, PM2, PM3, PP1). However, the functional evidence generated by the splicing assay now allows for the addition of PVS1 (null variant in a gene where loss-of-function is a known mechanism of disease) and PS3 (well-established *in vitro* or *in vivo* functional studies supportive of a damaging effect on the gene or gene product) criteria. This allows reclassification of the variant as ‘pathogenic’. Therefore, this work demonstrates the



importance of functional validation to confirm the effect of candidate variants on splicing to increase diagnostic rates for those with inherited disease.

Previously described homozygous *MME* patients typically have a phenotype consistent with late-onset axonal neuropathy. In contrast, three of the four affected siblings in Family 1 described childhood onset and the proband of Family 2 described symptom onset in early adulthood. It has also previously been reported that heterozygous *MME* variants can cause spinocerebellar ataxia type 43 (SCA43)<sup>80</sup> as well as autosomal dominant CMT<sup>3</sup>. However, the individuals in Family 1 who were *MME* c.1188+428A>G heterozygotes were all clinically assessed as neurologically normal, including an individual who is in their seventh decade. Homozygous affected individuals in Family 1 were noted to have a sensory ataxia rather than cerebellar ataxia, although MRI brain studies were not conducted. Therefore, our findings here do not support a role for *MME* c.1188+428A>G to cause SCA43 or autosomal dominant CMT, and further expand the phenotype of recessive CMT2T.

Understanding the specific effects of splice-affecting variants is crucial for developing potential therapeutic strategies. Antisense oligonucleotides (ASOs) that modulate splicing are an active area of research, including individualized approaches to treat rare genetic diseases<sup>81–83</sup>. Several antisense nucleotides that modify splicing have been approved by the United States Food and Drug Administration and have resulted in marked improvements in clinical outcomes in those with genetic diseases<sup>84–94</sup>. An FDA-approved “n-of-1” ASO, milasen, successfully blocked pathogenic pseudoexon inclusion in *MFSD8* in a patient with neuronal ceroid lipofuscinosis type 7<sup>94</sup>. ASOs which block pathogenic pseudoexons, such as that created by *MME* c.1188+428A>G, have also been described in *in vivo* preclinical models<sup>93,95–99</sup>. As such, individuals with the *MME* c.1188+428A>G variant may represent a

form of CMT that is treatable through personalized ASO therapy and warrants further investigation.

## Acknowledgements

This work was funded by the Medical Research Future Fund (MRFF) Genomics Health Futures Mission (APP2007681). JMP is supported by the Australian Government Research Training Program. IWD was supported by MRF2025138 & MRF2023126. Genomic analysis was supported by the Centre for Population Genomics (Garvan Institute of Medical Research and Murdoch Children's Research Institute) and was funded in part by a National Health and Medical Research Council investigator grant (2009982) and the Medical Research Future Fund (MRFF) Genomics Health Futures Mission (2008820).

## Figure Legends:

**Figure 1: The *MME* c.1188+428A>G (NM\_000902.5) variant segregates with recessive CMT in two families.** A) Family 1 pedigree showing the associated genotypes for the *MME* c.1188+428A>G (NM\_000902.5) variant. Affected individuals in the fifth generation are homozygous (G/G). Unaffected individuals in the fifth (V) and sixth (VI) generation are heterozygous (A/G). Squares represent males and circles represent females, solid symbol denotes affected individual. The double line in the fourth (IV) generation indicates a consanguineous relationship. The *MME* c.1188+428 genotype is denoted beneath individuals who underwent Sanger sequencing, with the pathogenic 'G' allele in red text. B) A pedigree showing the associated genotypes for *MME* c.1188+428A>G and *MME* c.467del in the index individual in Family 2. C-D) Haplotype phasing showed that the c.1188+428A>G (C) and c.467del (D) variants were present on alternative haplotypes (light red and light blue), thus inherited *in trans* in the proband of Family 2. Phased targeted ONT long-read sequencing reads were visualized using the Integrative Genomics Viewer (IGV; v2.17.3).

**Figure 2. An exon-trapping assay was used to analyze splicing changes caused by the *MME* c.1188+428A>G variant.** A) Schematic of the pSpliceExpress-*MME*<sub>WT</sub> (wild-type) and pSpliceExpress-*MME*<sub>c.1188+428A>G</sub> (variant) constructs. Both constructs consisted of an RSV LTR promoter region (blue) controlling transcription of a minigene of *MME* exons 12 and 13 (grey) flanked by *Ins2* exon 2 and *Ins2* exon 3 (black). The constructs differed in the presence of either an A (wild type: green text) or a G allele (mutant: red text) at *MME* c.1188+428A>G. i) The wild type sequence was not predicted to contain any strong splice sites when assessed using SpliceAI, with a score of 0.11 for the acceptor site (purple text) and 0.00 for the donor site (green text). ii) SpliceAI predicted that the *MME* c.1188+428A>G variant (red arrow) would create a strong splice donor site [Score: 0.97 ( $\Delta$  0.97); red text], which then strengthened the prediction of a splice acceptor site 83 bp upstream [Score 0.99

(Δ0.97); purple text]. The predicted 83 bp pseudoexon sequence is capitalized and boxed in red. B) The amplicon produced by the pSpliceExpress-*MME*<sub>c.1188+428A>G</sub> vector (464 bp) showed a visible increase in product size when compared to the amplicon produced by pSpliceExpress-*MME*<sub>WT</sub> (381 bp). The 158 bp RT-PCR product produced by both vectors indicated splicing and ligation of the flanking *Ins2* exon 2 and exon 3. Lanes: L: HyperLadder 100 bp (Bioline); WT: wild-type; NRTC: negative cDNA conversion control (no reverse transcriptase). NTC: negative PCR reaction control (no cDNA template). C) Sanger sequencing of the pSpliceExpress-*MME*<sub>WT</sub> RT-PCR product confirmed correct splicing between *MME* exon 12 and 13. D) Sanger sequencing of the pSpliceExpress-*MME*<sub>c.1188+428A>G</sub> RT-PCR product revealed the presence of a novel 83 bp pseudoexon (red) between *MME* exon 12 and 13. Abbreviations: RSV LTR: Rous Sarcoma Virus Long Terminal Repeat promoter; *Ins2*: rat preproinsulin 2 gene.

## References

1. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. *Clin Genet*. 1974;6:98-118.
2. Szigeti K, Lupski JR. Charcot-Marie-Tooth disease. *European Journal of Human Genetics*. 2009;17(6):703-710. doi:10.1038/ejhg.2009.31
3. Senderek J, Lassuthova P, Kabzińska D, et al. The genetic landscape of axonal neuropathies in the middle-aged and elderly. *Neurology*. 2020;95(24). doi:10.1212/WNL.00000000000011132
4. Higuchi Y. Mutations in MME cause an autosomal-recessive Charcot-Marie-Tooth disease type 2. *Ann Neurol*. 2016;79:659-672.
5. Record CJ, Pipis M, Skorupinska M, et al. Whole genome sequencing increases the diagnostic rate in Charcot-Marie-Tooth disease. *Brain*. Published online March 14, 2024. doi:10.1093/brain/awae064
6. Jamiri Z, Khosravi R, Heidari MM, Kiani E, Gharechahi J. A nonsense mutation in *MME* gene associates with autosomal recessive late-onset Charcot-Marie-Tooth disease. *Mol Genet Genomic Med*. 2022;10(5). doi:10.1002/mgg3.1913
7. Taghizadeh S, Vazehan R, Beheshtian M, et al. Molecular Diagnosis of Hereditary Neuropathies by Whole Exome Sequencing and Expanding the Phenotype Spectrum. *Arch Iran Med*. 2020;23(7):426-433. doi:10.34172/AIM.2020.39
8. Ando M, Higuchi Y, Yuan J, et al. Comprehensive Genetic Analyses of Inherited Peripheral Neuropathies in Japan: Making Early Diagnosis Possible. *Biomedicines*. 2022;10(7):1546. doi:10.3390/biomedicines10071546
9. Megarbane A, Bizzari S, Deepthi A, et al. A 20-year Clinical and Genetic Neuromuscular Cohort Analysis in Lebanon: An International Effort. *J Neuromuscul Dis*. 2022;9(1):193-210. doi:10.3233/JND-210652
10. Høyer H, Hilmarsen HT, Sunder-Plassmann R, et al. A polymorphic AT-repeat causes frequent allele dropout for an *MME* mutational hotspot exon. *J Med Genet*. 2022;59(10):1024-1026. doi:10.1136/jmedgenet-2021-108281
11. Dupuis M, Raymackers JM, Ackermans N, Boulanger S, Verellen-Dumoulin C. Hereditary axonal neuropathy related to MME gene mutation in a family with fetomaternal alloimmune glomerulonephritis. *Acta Neurol Belg*. 2020;120(1):149-154. doi:10.1007/s13760-020-01275-9
12. Krämer HH, He L, Lu B, Birklein F, Sommer C. Increased pain and neurogenic inflammation in mice deficient of neutral endopeptidase. *Neurobiol Dis*. 2009;35(2):177-183. doi:10.1016/j.nbd.2008.11.002

- 467 13. Gemelli C, Geroldi A, Massucco S, et al. Genetic Workup for Charcot-Marie-Tooth  
468 Neuropathy: A Retrospective Single-Site Experience Covering 15 Years. *Life (Basel)*.  
469 2022;12(3). doi:10.3390/life12030402
- 470 14. Candayan A, Parman Y, Battaloğlu E. Clinical and Genetic Survey for Charcot-Marie-  
471 Tooth Neuropathy Based on the Findings in Turkey, a Country with a High Rate of  
472 Consanguineous Marriages. *Balkan Med J*. 2022;39(1):3.  
473 doi:10.4274/BALKANMEDJ.GALENOS.2021.2021-11-13
- 474 15. Rudnik-Schöneborn S, Tölle D, Senderek J, et al. Diagnostic algorithms in Charcot-  
475 Marie-Tooth neuropathies: experiences from a German genetic laboratory on the basis  
476 of 1206 index patients. *Clin Genet*. 2016;89(1):34-43. doi:10.1111/cge.12594
- 477 16. Fridman V, Bundy B, Reilly MM, et al. CMT subtypes and disease burden in patients  
478 enrolled in the Inherited Neuropathies Consortium natural history study: a cross-  
479 sectional analysis. 2015;86(8):873-878. doi:10.1136/jnnp-2014-308826
- 480 17. Ma Y, Duan X, Liu X, Fan D. Clinical and mutational spectrum of paediatric Charcot-  
481 Marie-Tooth disease in a large cohort of Chinese patients. *Front Genet*. 2023;14.  
482 doi:10.3389/fgene.2023.1188361
- 483 18. Lord J, Baralle D. Splicing in the Diagnosis of Rare Disease: Advances and  
484 Challenges. *Front Genet*. 2021;12:689892. doi:10.3389/fgene.2021.689892
- 485 19. Wang R, Helbig I, Edmondson AC, Lin L, Xing Y. Splicing defects in rare diseases:  
486 transcriptomics and machine learning strategies towards genetic diagnosis. *Brief*  
487 *Bioinform*. 2023;24(5). doi:10.1093/bib/bbad284
- 488 20. Anna A, Monika G. *Splicing Mutations in Human Genetic Disorders: Examples,*  
489 *Detection, and Confirmation*. Vol 59. Springer Verlag; 2018:253-268.  
490 doi:10.1007/s13353-018-0444-7
- 491 21. Corrado L, Magri S, Bagarotti A, et al. A novel synonymous mutation in the MPZ  
492 gene causing an aberrant splicing pattern and Charcot-Marie-Tooth disease type 1b.  
493 *Neuromuscular Disorders*. 2016;26(8):516-520. doi:10.1016/j.nmd.2016.05.011
- 494 22. Boaretto F, Vettori A, Casarin A, et al. Severe CMT type 2 with fatal encephalopathy  
495 associated with a novel MFN2 splicing mutation. *Neurology*. 2010;74(23).  
496 doi:10.1212/WNL.0b013e3181e240f9
- 497 23. Engholm M, Sekler J, Schöndorf DC, et al. A novel mutation in LRSAM1 causes  
498 axonal Charcot-Marie-Tooth disease with dominant inheritance. *BMC Neurol*.  
499 2014;14(1):118. doi:10.1186/1471-2377-14-118
- 500 24. Cassini TA, Duncan L, Rives LC, et al. Whole genome sequencing reveals novel  
501 *IGHMBP2* variant leading to unique cryptic splice site and Charcot-Marie-Tooth  
502 phenotype with early onset symptoms. *Mol Genet Genomic Med*. 2019;7(6):e00676.  
503 doi:10.1002/mgg3.676
- 504 25. Echaniz-Laguna A, Latour P, Echaniz-Laguna A, Latour P, Echaniz-Laguna A,  
505 Latour P. A cryptic splicing mutation in the INF2 gene causing Charcot-Marie-Tooth

- 506 disease with minimal glomerular dysfunction. *Journal of the Peripheral Nervous*  
507 *System*. 2019;24(1):120-124. doi:10.1111/jns.12308
- 508 26. Ylikallio E, Woldegebriel R, Tumati M, et al. MCM3AP in recessive Charcot-Marie-  
509 Tooth neuropathy and mild intellectual disability. *Brain*. 2017;140(8):2093-2103.  
510 doi:10.1093/brain/awx138
- 511 27. Numakura C, Lin C, Ikegami T, Guldberg P, Hayasaka K. Molecular analysis in  
512 Japanese patients with Charcot-Marie-Tooth disease: DGGE analysis for PMP22,  
513 MPZ, and Cx32/GJB1 mutations. *Hum Mutat*. 2002;20(5):392-398.  
514 doi:10.1002/humu.10134
- 515 28. Flusser H, Halperin D, Kadir R, Shorer Z, Shelef I, Birk OS. Novel SBF1 splice-site  
516 null mutation broadens the clinical spectrum of Charcot-Marie-Tooth type 4B3  
517 disease. *Clin Genet*. 2018;94(5):473-479. doi:10.1111/cge.13419
- 518 29. Hayashi M, Abe A, Murakami T, et al. Molecular analysis of the genes causing  
519 recessive demyelinating Charcot-Marie-Tooth disease in Japan. *J Hum Genet*.  
520 2013;58(5):273-278. doi:10.1038/jhg.2013.15
- 521 30. DiVincenzo C, Elzinga CD, Medeiros AC, et al. The allelic spectrum of Charcot-  
522 Marie-Tooth disease in over 17,000 individuals with neuropathy. *Mol Genet Genomic*  
523 *Med*. 2014;2(6):522-529. doi:10.1002/mgg3.106
- 524 31. Martikainen MH, Kytövuori L, Majamaa K. Novel mitofusin 2 splice-site mutation  
525 causes Charcot-Marie-Tooth disease type 2 with prominent sensory dysfunction.  
526 *Neuromuscular Disorders*. 2014;24(4):360-364. doi:10.1016/j.NMD.2014.01.007
- 527 32. Piscoquito G, Saveri P, Magri S, et al. Screening for SH3TC2 gene mutations in a  
528 series of demyelinating recessive Charcot-Marie-Tooth disease (CMT4). *J Peripher*  
529 *Nerv Syst*. 2016;21(3):142-149. doi:10.1111/jns.12175
- 530 33. Benedetti S, Previtali SC, Coviello S, et al. Analyzing histopathological features of  
531 rare Charcot-Marie-Tooth neuropathies to unravel their pathogenesis. *Arch Neurol*.  
532 2010;67(12):1498-1505. doi:10.1001/archneurol.2010.303
- 533 34. Li MY, Yin M, Yang L, et al. A novel splicing mutation in 5'UTR of GJB1 causes X-  
534 linked Charcot—Marie—tooth disease. *Mol Genet Genomic Med*. 2023;11(3):e2108.  
535 doi:10.1002/MGG3.2108
- 536 35. Boso F, Taioli F, Cabrini I, Cavallaro T, Fabrizi GM. Aberrant Splicing in GJB1 and  
537 the Relevance of 5' UTR in CMTX1 Pathogenesis. *Brain Sci*. 2020;11(1):24.  
538 doi:10.3390/brainsci11010024
- 539 36. Tomaselli PJPPJ, Rossor AM, Horga A, et al. Mutations in noncoding regions in GJB1  
540 are a major cause of X-linked CMT. *Neurology*. 2017;88(15):1445-1453.  
541 doi:10.1212/WNL.0000000000003819
- 542 37. Pravinbabu P, Holla V V, Phulpagar P, et al. A splice altering variant in NDRG1 gene  
543 causes Charcot-Marie-Tooth disease, type 4D. *Neurol Sci*. 2022;43(7):4463-4472.  
544 doi:10.1007/s10072-022-05893-4



- 545 38. Shchagina O, Orlova M, Murtazina A, Filatova A, Skoblov M, Dadali E. Evaluation of  
546 Pathogenicity and Causativity of Variants in the MPZ and SH3TC2 Genes in a Family  
547 Case of Hereditary Peripheral Neuropathy. *Int J Mol Sci.* 2023;24(12).  
548 doi:10.3390/ijms24129786
- 549 39. Taioli F, Cabrini I, Cavallaro T, Simonati A, Testi S, Fabrizi GM. Déjerine-Sottas  
550 syndrome with a silent nucleotide change of myelin protein zero gene. *Journal of the*  
551 *Peripheral Nervous System.* 2011;16(1):59-64. doi:10.1111/j.1529-8027.2011.00319.x
- 552 40. Sabet A, Li J, Ghandour K, et al. Skin biopsies demonstrate MPZ splicing  
553 abnormalities in Charcot-Marie-Tooth neuropathy 1B. *Neurology.* 2006;67(7):1141-  
554 1146. doi:10.1212/01.wnl.0000238499.37764.b1
- 555 41. Lupo V. Characterising the phenotype and mode of inheritance of patients with  
556 inherited peripheral neuropathies carrying MME mutations. *J Med Genet.*  
557 2018;55:814-823.
- 558 42. Masingue M, Perrot J, Carlier RY, Piguet-Lacroix G, Latour P, Stojkovic T. WES  
559 homozygosity mapping in a recessive form of Charcot-Marie-Tooth neuropathy  
560 reveals intronic GDAP1 variant leading to a premature stop codon. *Neurogenetics.*  
561 2018;19(2):67-76. doi:10.1007/s10048-018-0539-7
- 562 43. Duyk GM, Kim SW, Myers RM, Cox DR. Exon trapping: a genetic screen to identify  
563 candidate transcribed sequences in cloned mammalian genomic DNA. *Proceedings of*  
564 *the National Academy of Sciences.* 1990;87(22):8995-8999.  
565 doi:10.1073/pnas.87.22.8995
- 566 44. Micale L, Morlino S, Schirizzi A, et al. Exon-Trapping Assay Improves Clinical  
567 Interpretation of COL11A1 and COL11A2 Intronic Variants in Stickler Syndrome  
568 Type 2 and Otospondylomegapiphyseal Dysplasia. *Genes (Basel).* 2020;11(12):1513.  
569 doi:10.3390/genes11121513
- 570 45. Grosz BR, Tisch S, Tchan MC, et al. A novel synonymous KMT2B variant in a patient  
571 with dystonia causes aberrant splicing. *Mol Genet Genomic Med.* 2022;10(5).  
572 doi:10.1002/MGG3.1923
- 573 46. Mutai H, Wasano K, Momozawa Y, et al. Variants encoding a restricted carboxy-  
574 terminal domain of SLC12A2 cause hereditary hearing loss in humans. *PLoS Genet.*  
575 2020;16(4). doi:10.1371/journal.pgen.1008643
- 576 47. Knapp KM, Sullivan R, Murray J, et al. Linked-read genome sequencing identifies  
577 biallelic pathogenic variants in DONSON as a novel cause of Meier-Gorlin syndrome.  
578 *J Med Genet.* 2020;57(3):195-202. doi:10.1136/jmedgenet-2019-106396
- 579 48. Starokadomskyy P, Gemelli T, Rios JJ, et al. DNA polymerase- $\alpha$  regulates the  
580 activation of type I interferons through cytosolic RNA:DNA synthesis. *Nat Immunol.*  
581 2016;17(5):495-504. doi:10.1038/ni.3409
- 582 49. Varga L, Danis D, Skopkova M, et al. Novel EYA4 variant in Slovak family with late  
583 onset autosomal dominant hearing loss: A case report. *BMC Med Genet.* 2019;20(1).  
584 doi:10.1186/s12881-019-0806-y



- 585 50. Legendre M, Rodriguez-Ballesteros M, Rossi M, et al. CHARGE syndrome: A  
586 recurrent hotspot of mutations in CHD7 IVS25 analyzed by bioinformatic tools and  
587 minigene assays /631/208 /692/308 brief-communication. *European Journal of Human*  
588 *Genetics*. 2018;26(2):287-292. doi:10.1038/s41431-017-0007-0
- 589 51. Abdulhay NJ, Fiorini C, Verboon JM, et al. Impaired human hematopoiesis due to a  
590 cryptic intronic GATA1 splicing mutation. *Journal of Experimental Medicine*.  
591 2019;216(5):1050-1060. doi:10.1084/jem.20181625
- 592 52. Kishore S, Khanna A, Stamm S. Rapid generation of splicing reporters with  
593 pSpliceExpress. *Gene*. 2008;427(1-2):104-110. doi:10.1016/j.gene.2008.09.021
- 594 53. Pedersen BS, Bhetariya PJ, Brown J, et al. Somalier: rapid relatedness estimation for  
595 cancer and germline studies using efficient genome sketches. *Genome Med*.  
596 2020;12(1):62. doi:10.1186/s13073-020-00761-2
- 597 54. Pais LS, Snow H, Weisburd B, et al. seqr: A web-based analysis and collaboration tool  
598 for rare disease genomics. *Hum Mutat*. 2022;43(6):698-707.  
599 doi:10.1002/HUMU.24366
- 600 55. Stark Z, Foulger RE, Williams E, et al. Scaling national and international improvement  
601 in virtual gene panel curation via a collaborative approach to discordance resolution.  
602 *Am J Hum Genet*. 2021;108(9):1551-1557. doi:10.1016/j.ajhg.2021.06.020
- 603 56. Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting Splicing  
604 from Primary Sequence with Deep Learning. *Cell*. 2019;176(3):535-548.e24.  
605 doi:10.1016/j.cell.2018.12.015
- 606 57. Payne A, Holmes N, Clarke T, Munro R, Debebe BJ, Loose M. Readfish enables  
607 targeted nanopore sequencing of gigabase-sized genomes. *Nat Biotechnol*.  
608 2021;39(4):442-450. doi:10.1038/s41587-020-00746-x
- 609 58. Stevanovski I, Chintalaphani SR, Gamaarachchi H, et al. Comprehensive genetic  
610 diagnosis of tandem repeat expansion disorders with programmable targeted nanopore  
611 sequencing. *Sci Adv*. 2022;8(9). doi:10.1126/SCIADV.ABM5386
- 612 59. Gamaarachchi H, Samarakoon H, Jenner SP, et al. Fast nanopore sequencing data  
613 analysis with SLOW5. *Nat Biotechnol*. 2022;40(7):1026-1029. doi:10.1038/s41587-  
614 021-01147-4
- 615 60. Samarakoon H, Ferguson JM, Jenner SP, et al. Flexible and efficient handling of  
616 nanopore sequencing signal data with slow5tools. *Genome Biol*. 2023;24(1):69.  
617 doi:10.1186/s13059-023-02910-3
- 618 61. Li H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics*.  
619 2018;34(18):3094-3100. doi:10.1093/bioinformatics/bty191
- 620 62. Zheng Z, Li S, Su J, Leung AWS, Lam TW, Luo R. Symphonizing pileup and full-  
621 alignment for deep learning-based long-read variant calling. *Nat Comput Sci*.  
622 2022;2(12):797-803. doi:10.1038/s43588-022-00387-x

- 623 63. Martin M, Patterson M, Garg S, et al. WhatsHap: fast and accurate read-based phasing.  
624 Published online 2016. doi:10.1101/085050
- 625 64. Robinson JT, Thorvaldsdóttir H, Winckler W, et al. Integrative Genomics Viewer. *Nat*  
626 *Biotechnol.* 2011;29(1):24. doi:10.1038/NBT.1754
- 627 65. Zeng Z, Bromberg Y. Predicting Functional Effects of Synonymous Variants: A  
628 Systematic Review and Perspectives. *Front Genet.* 2019;0:914.  
629 doi:10.3389/FGENE.2019.00914
- 630 66. Kishore Jaganathan A, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting  
631 Splicing from Primary Sequence with Deep Learning In Brief A deep neural network  
632 precisely models mRNA splicing from a genomic sequence and accurately predicts  
633 noncoding cryptic splice mutations in patients with rare genetic diseases. Predicting  
634 Splicing from Primary Sequence with Deep Learning. *Cell.* 2018;176:535-548.  
635 doi:10.1016/j.cell.2018.12.015
- 636 67. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic  
637 variation. *Nucleic Acids Res.* 2001;29(1):308-311. Accessed March 5, 2019.  
638 <http://www.ncbi.nlm.nih.gov/pubmed/11125122>
- 639 68. Chen S, Francioli LC, Goodrich JK, et al. A genomic mutational constraint map using  
640 variation in 76,156 human genomes. *Nature.* 2024;625(7993):92-100.  
641 doi:10.1038/s41586-023-06045-0
- 642 69. All of Us Research Program Investigators, Denny JC, Rutter JL, et al. The “All of Us”  
643 Research Program. *N Engl J Med.* 2019;381(7):668-676. doi:10.1056/NEJMs1809937
- 644 70. Taliun D, Harris DN, Kessler MD, et al. Sequencing of 53,831 diverse genomes from  
645 the NHLBI TOPMed Program. *Nature.* 2021;590(7845):290-299. doi:10.1038/s41586-  
646 021-03205-y
- 647 71. Kent WJ. <tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool. *Genome*  
648 *Res.* 2002;12(4):656-664. doi:10.1101/gr.229202
- 649 72. Castle JC. SNPs occur in regions with less genomic sequence conservation. *PLoS One.*  
650 2011;6(6):e20660. doi:10.1371/journal.pone.0020660
- 651 73. Boisson M, Arrondel C, Cagnard N, et al. A wave of deep intronic mutations in X-  
652 linked Alport syndrome. *Kidney Int.* 2023;104(2):367-377.  
653 doi:10.1016/j.kint.2023.05.006
- 654 74. Qian X, Wang J, Wang M, et al. Identification of Deep-Intronic Splice Mutations in a  
655 Large Cohort of Patients With Inherited Retinal Diseases. *Front Genet.*  
656 2021;12:647400. doi:10.3389/fgene.2021.647400
- 657 75. Di Scipio M, Tavares E, Deshmukh S, et al. Phenotype Driven Analysis of Whole  
658 Genome Sequencing Identifies Deep Intronic Variants that Cause Retinal Dystrophies  
659 by Aberrant Exonization. *Invest Ophthalmol Vis Sci.* 2020;61(10):36.  
660 doi:10.1167/iovs.61.10.36

- 661 76. Xie Z, Sun C, Liu Y, et al. Practical approach to the genetic diagnosis of unsolved  
662 dystrophinopathies: a stepwise strategy in the genomic era. *J Med Genet*.  
663 2021;58(11):743-751. doi:10.1136/jmedgenet-2020-107113
- 664 77. Zaum AK, Stüve B, Gehrig A, et al. Deep intronic variants introduce DMD  
665 pseudoexon in patient with muscular dystrophy. *Neuromuscul Disord*. 2017;27(7):631-  
666 634. doi:10.1016/j.nmd.2017.04.003
- 667 78. Anna A, Monika G. Splicing mutations in human genetic disorders: examples,  
668 detection, and confirmation. *J Appl Genet*. 2018;59(3):253-268. doi:10.1007/s13353-  
669 018-0444-7
- 670 79. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of  
671 sequence variants: A joint consensus recommendation of the American College of  
672 Medical Genetics and Genomics and the Association for Molecular Pathology.  
673 *Genetics in Medicine*. 2015;17(5):405-424. doi:10.1038/gim.2015.30
- 674 80. Depondt C, Donatello S, Rai M, et al. MME mutation in dominant spinocerebellar  
675 ataxia with neuropathy (SCA43). *Neurol Genet*. 2016;2(5):e94.  
676 doi:10.1212/NXG.0000000000000094
- 677 81. Kim J, Woo S, de Gusmao CM, et al. A framework for individualized splice-switching  
678 oligonucleotide therapy. *Nature*. 2023;619(7971):828-836. doi:10.1038/s41586-023-  
679 06277-0
- 680 82. Chen S, Heendeniya SN, Le BT, et al. Splice-Modulating Antisense Oligonucleotides  
681 as Therapeutics for Inherited Metabolic Diseases. *BioDrugs*. 2024;38(2):177-203.  
682 doi:10.1007/s40259-024-00644-7
- 683 83. Santos JI, Gonçalves M, Matos L, et al. Splicing Modulation as a Promising  
684 Therapeutic Strategy for Lysosomal Storage Disorders: The Mucopolysaccharidoses  
685 Example. *Life*. 2022;12(5):608. doi:10.3390/life12050608
- 686 84. Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of  
687 Duchenne muscular dystrophy. *Ann Neurol*. 2013;74(5):637-647.  
688 doi:10.1002/ana.23982
- 689 85. Frank DE, Schnell FJ, Akana C, et al. Increased dystrophin production with golodirsen  
690 in patients with Duchenne muscular dystrophy. *Neurology*. 2020;94(21):e2270-e2282.  
691 doi:10.1212/WNL.00000000000009233
- 692 86. Heo YA. Golodirsen: First Approval. *Drugs*. 2020;80(3):329-333.  
693 doi:10.1007/s40265-020-01267-2
- 694 87. Clemens PR, Rao VK, Connolly AM, et al. Safety, Tolerability, and Efficacy of  
695 Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53  
696 Skipping: A Phase 2 Randomized Clinical Trial. *JAMA Neurol*. 2020;77(8):982-991.  
697 doi:10.1001/jamaneurol.2020.1264
- 698 88. Shirley M. Casimersen: First Approval. *Drugs*. 2021;81(7):875-879.  
699 doi:10.1007/s40265-021-01512-2

89. Wurster CD, Winter B, Wollinsky K, et al. Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients. *J Neurol*. 2019;266(1):183-194. doi:10.1007/s00415-018-9124-0
90. Osredkar D, Jílková M, Butenko T, et al. Children and young adults with spinal muscular atrophy treated with nusinersen. *Eur J Paediatr Neurol*. 2021;30:1-8. doi:10.1016/j.ejpn.2020.11.004
91. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. *N Engl J Med*. 2018;378(7):625-635. doi:10.1056/NEJMoa1710504
92. Bianchi L, Sframeli M, Vantaggiato L, et al. Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients. *Int J Mol Sci*. 2021;22(9). doi:10.3390/ijms22094329
93. Kim J, Woo S, de Gusmao CM, et al. A framework for individualized splice-switching oligonucleotide therapy. *Nature*. 2023;619(7971):828-836. doi:10.1038/s41586-023-06277-0
94. Kim J, Hu C, Moufawad El Achkar C, et al. Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. *N Engl J Med*. 2019;381(17):1644-1652. doi:10.1056/NEJMoa1813279
95. Yamada M, Maeta K, Suzuki H, et al. Successful skipping of abnormal pseudoexon by antisense oligonucleotides in vitro for a patient with beta-propeller protein-associated neurodegeneration. *Sci Rep*. 2024;14(1):6506. doi:10.1038/s41598-024-56704-z
96. Aguti S, Bolduc V, Ala P, et al. Exon-Skipping Oligonucleotides Restore Functional Collagen VI by Correcting a Common COL6A1 Mutation in Ullrich CMD. *Mol Ther Nucleic Acids*. 2020;21:205-216. doi:10.1016/J.OMTN.2020.05.029
97. Kim J, Hu C, Moufawad El Achkar C, et al. Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. *N Engl J Med*. 2019;381(17):1644-1652. doi:10.1056/NEJMOA1813279
98. Dominov JA, Uyan Ö, McKenna Yasek D, et al. Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation. *Ann Clin Transl Neurol*. 2019;6(4):642-654. doi:10.1002/acn3.738
99. Martínez-Pizarro A, Leal F, Holm LL, et al. Antisense Oligonucleotide Rescue of Deep-Intronic Variants Activating Pseudoexons in the 6-Pyruvoyl-Tetrahydropterin Synthase Gene. *Nucleic Acid Ther*. 2022;32(5):378-390. doi:10.1089/nat.2021.0066

Table 1. Phenotypic characterization of individuals with recessive CMT *MME* variants reported in this manuscript. Abbreviations- AFO: Ankle foot orthoses; CMTNS: Charcot-Marie-Tooth Neuropathy Score; UL/LL: Upper Limb/Lower Limb

Family #	Family 1				Family 2
Individual	V:1	V:3	V:4	V:6	II:1
Sex	M	F	M	M	F
Onset	Fourth decade	Childhood	Childhood	Childhood	Early-adult
Age at evaluation (years)	60-65	65-70	65-70	65-70	50-55
Presenting symptom	Gait unsteadiness	Difficulty running	Difficulty sitting on crossed legs during childhood	Difficulty running, multiple ankle sprains	Bilateral leg weakness and sensory disturbance
Atrophy UL/LL	Yes/yes	Yes/yes	Yes/yes	Yes/yes	No/Yes (left calf only)
Foot deformity	None	Pes cavus/hammer toes	-	Pes cavus	Pes cavus
Tone UL/LL	Normal/reduced	Normal/normal	Normal, increased		Normal/normal
Shoulder abduction	5	5	3	5	4
Elbow flexion	4	5	3	4	5
Elbow extension	4	5	3	4	5

Finger abduction	2	4	3	1	4
Hip flexion	4	3	3	3	4
Knee extension	4	3	3	4	4
Knee flexion	4	3	3	4	4
Ankle dorsiflexion	0	0	3	1	3
Ankle plantarflexion	0	0	3	0	4
Deep tendon reflexes UL/LL	Absent/absent	Absent ankle	Hyperreflexia knee, absent ankle	Absent/absent	Normal/ reduced ankle reflexes
Plantars	Absent	-	Absent	Flexor	Flexor
Proprioception UL/LL	Normal/reduced to the MTP	-	-	Normal/reduced to the ankle	Normal/reduced to ankle
Vibration UL/LL	Normal/reduced to ankle	Absent in toes	-	Reduced to wrist/reduced to knees	Reduced to mid-shin
Pinprick UL/LL	Normal/reduced to ankle	Normal/reduced to the mid shin	Reduced to elbows/reduced to knees	Reduced to PIP joint/reduced to knees	Reduced to mid-shin Reduced dorsum hand
Temperature sensation UL/LL	Normal/reduced to ankle	-	-	Reduced to wrist/reduced to above	Reduced to mid-shin

				knee	
Other symptoms/signs	Cough	GORD and cough	Corticospinal tract signs	Nil	Fatty infiltration on left gastrocnemius
Gait	High steppage/ataxic	High steppage/ataxic	Steppage gait	High steppage/ataxic	High steppage
Romberg's sign	Positive	Positive		Positive	Mild sway
Mobility aids	AFO, walking stick and mobility scooter	AFO, walker	AFO, walker, mobility scooter	Wheelchair	AFO, elbow crutch
CMTNS (version 2)	31	-	28/36	36	15

Table 2. Nerve conduction study (NCS) findings of individuals with recessive CMT *MME* variants reported in this manuscript. Abbreviations: APB: abductor pollicis brevis; ADM: abductor digiti minimi; EDB: extensor hallucis brevis; FHB: flexor hallucis brevis; CMAP: compound motor action potential; CV: conduction velocity; NR: no response; SNAP: sensory nerve action potential; R: right, L:left.


Family #	Family 1		Family 2
Individual	V:1	V:6	II:1
Age at NCS (years)	60-65	65-70	55-60
Median nerve (digit II) [orthodromic(R)]			
SNAP (uV)	NR	NR	6.6
CV (m/s)	NR	NR	50
Ulnar nerve (digit V) [orthodromic(R)]			
SNAP (uV)	NR	1	4.9
CV (m/s)	NR	40.2	51
Sural nerve [orthodromic(R)]			
SNAP (uV)	NR	NR	NR
CV (m/s)	NR	NR	NR
Sural nerve [orthodromic(L)]			




SNAP (uV)	NR	NR	NR
CV (m/s)	NR	NR	NR
Median nerve (APB) (R)			
CMAP (mV)	NR	NR	4.8
CV (m/s)	NR	NR	41
Ulnar nerve (ADM) (R)			
CMAP (mV)	2	0.6	6.6
CV (m/s)	44.4	44.7	52 (wrist-below elbow) 57 (wrist-above elbow)
Peroneal nerve (EDB) (R)			
CMAP (mV)	NR	NR	NR
CV (m/s)	NR	NR	NR
Tibial nerve (FHB) (L)			
CMAP (mV)	NR	NR	NR
CV (m/s)	NR	NR	NR
Needle EMG	Absent voluntary units in the right tibialis anterior and medial gastrocnemius muscles, as well as denervation-reinnervation changes in	Absent recruitment of motor units in the right tibialis anterior, medial gastrocnemius, first dorsal interosseous and vastus lateralis	Reduced recruitment of motor units in the right tibialis anterior and right vastus medialis muscles. Discrete recruitment of muscle fibres in the

	the right vastus lateralis muscle.	muscles. Denervation-reinnervation changes were evident in the right deltoid, biceps brachii and triceps brachii muscles.	right gastrocnemius muscle.
--	------------------------------------	---	-----------------------------


a



b




c



d



a




i.

ttcaggtgctcattgcacactggacatatacacagatggacaatattgatgtgggcagtctattgaaagtaccctacctggaggttaaataag

↑ Acceptor SpliceAI Score: 0.11

↑ Donor SpliceAI Score: 0.00

medRxiv preprint doi: <https://doi.org/10.1101/2024.04.22.24306048>; this version posted April 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




ii.

ttcagGTGCTCATTGCACACTGGACATATACACAGATGGACAATATTGATGTGGGCAGTCTATTGAAAGTACCCCTACCTGGAGTTAAgtaag

↑ Acceptor SpliceAI Score: 0.99 (Δ 0.88)

↑ Donor SpliceAI Score: 0.97 (Δ 0.97)

b



c



d

